Compare BZH & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZH | VOR |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.0M | 776.5M |
| IPO Year | 1995 | 2021 |
| Metric | BZH | VOR |
|---|---|---|
| Price | $25.71 | $15.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $32.00 | ★ $45.33 |
| AVG Volume (30 Days) | ★ 898.7K | 800.4K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,087,739,000.00 | N/A |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $10.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.83 | $0.18 |
| 52 Week High | $28.33 | $49.95 |
| Indicator | BZH | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 65.26 | 49.69 |
| Support Level | $24.18 | $13.73 |
| Resistance Level | $27.35 | $16.87 |
| Average True Range (ATR) | 1.17 | 0.98 |
| MACD | 0.38 | -0.03 |
| Stochastic Oscillator | 95.33 | 26.90 |
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in states and metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the sources of revenue for the company. Its segments involve: West segment that includes Arizona, California, Nevada, and Texas; East segment that includes Delaware, Indiana, Maryland, Tennessee, and Virginia; and Southeast segment which includes Florida, Georgia, North Carolina, and South Carolina.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.